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Primary ciliary dyskinesia (PCD) is a rare heterogenous condition that causes progressive suppurative lung disease,
chronic rhinosinusitis, chronic otitis media, infertility and abnormal situs. ‘Better Experimental Approaches to Treat
Primary Ciliary Dyskinesia’ (BEAT-PCD) is a network of scientists and clinicians coordinating research from basic
science through to clinical care with the intention of developing treatments and diagnostics that lead to improved
long-term outcomes for patients. BEAT-PCD activities are supported by EU Framework Programme Horizon 2020
funded COST Action (BM1407). The Inaugural Conference of BEAT-PCD was held in December 2015 in
Southampton, UK. The conference attracted ninety-six scientists, clinicians, allied health professionals, industrial
partners and patient representatives from twenty countries. We aimed to identify the needs for PCD research and
clinical care, particularly focussing on basic science, epidemiology, diagnostic testing, clinical management and
clinical trials. The multidisciplinary conference provided an interactive platform for exchanging ideas through a
program of lectures, poster presentations, breakout sessions and workshops. This allowed us to develop plans for
collaborative studies. In this report, we summarize the meeting, highlight developments, and discuss open
questions thereby documenting ongoing developments in the field of PCD research.Introduction
PCD is a rare heterogeneous disorder characterized by im-
paired mucociliary clearance due to abnormal ciliary func-
tion, which is usually but not always associated with
abnormal ciliary ultrastructure [1, 2]. Clinical manifestations* Correspondence: jlucas1@soton.ac.uk
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recurrent lower and upper respiratory tract symptoms
which present soon after birth. Neonatal symptoms range
in severity from mild transient tachypnoea to significant
respiratory failure requiring prolonged respiratory support
[3]. Recent data suggests that PCD has a progressive, and
potentially severe long-term course of lower airway dis-
ease [4] with recurrent infections leading to bronchiectasis
and impaired lung function. Male infertility is common
since sperm flagella have a similar ultrastructure to cilia,
whereas the incidence of female infertility and of ectopic
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cilia establish left-right asymmetry [6] and nearly half of
PCD patients exhibit situs inversus [7] and 6–12% have
heterotaxic syndromes (abnormal arrangement across the
left-right axis of the body) which can be associated with
complex congenital cardiac defects [7–9]. PCD is a genet-
ically heterogeneous disorder, typically caused by an auto-
somal recessive mode of inheritance (more than 30 genes
identified to date); diagnostic and molecular features differ
according to the specific gene and mutations. Diagnosis is
currently based on combination testing, which normally
includes nasal nitric oxide (nNO) measurements, ciliary
beat frequency (CBF) and pattern (CBP) using high-speed
video microscopy analysis (HSVMA), ultrastructural de-
fects using transmission electron microscopy (TEM), and
genetic testing [10].
Data is lacking on genetic and environmental determi-
nants of clinical phenotype, severity, or long-term prog-
nosis. Reported prevalence of PCD varies across Europe
reflecting true variability as well as differences in access
to diagnostic facilities [10]. Prevalence is estimated
1:2000–1:40,000, with true prevalence probably 1:10,000
or higher [11]. This reflects a significant disease burden,
causing progressive disease in 74,000 Europeans. A quar-
ter of adult PCD patients in USA exhibit severe lung dis-
ease requiring long term oxygen or lung transplantation
[2] highlighting the need for treatments to limit disease
progression. Hampering the trajectory of respiratory de-
cline would have positive implications for health care ex-
penditure and associated benefits to individuals, carers
and society. As for other rare diseases the evidence base
for PCD is sparse and there has been little clinical or
translational research, with treatment strategies inappro-
priately extrapolated from other diseases [10, 12, 13] e.g.,
treatments for lung manifestations are derived from cystic
fibrosis (CF) guidelines despite different pathophysiology.
Over recent years advances made in the field of PCD
have been attained through collaborations of clinicians on
the one hand, and scientists on the other. Several inter-
national initiatives have stimulated these advances includ-
ing the North American Genetic Disorders of Mucociliary
Clearance Consortium (GDMCC) [8, 14–16], two network
European Respiratory Society (ERS) Task Forces [10, 11,
17, 18] and European FP7-funded BESTCILIA [19–21].
To maintain this momentum and build on successes of
previous collaborations, there was a need for a network to
bring clinicians and scientists together. BEAT-PCD
(http://www.beatpcd.org/) is a Europe-led collaboration
supported by EU- Framework Horizon 2020 funded
COST Action (BM1407). The international network in-
cludes experts from multidisciplinary clinical specialties
(e.g., paediatric & adult pulmonology, ENT, physiotherapy,
fertility) motivated for collaborative research with scien-
tists from diverse backgrounds (e.g., genetics, imaging, cellbiology, microbiology, bioinformatics) and different coun-
tries. BEAT-PCD aims to facilitate PCD-related research
to identify mechanisms, study disease patterns and pro-
gression, define outcome measures, improve clinical man-
agement and identify high priority therapies. The Action
aims to act as a platform throughout the process, from
preclinical studies to clinical trials.
The activities of BEAT-PCD are coordinated through
four highly integrated Workgroups: Basic Science,
Epidemiology, Clinical Care and Clinical Trials (Fig. 1).
BEAT-PCD’s overarching mission is to provide a plat-
form to encourage networking, to advance research
underpinning diagnosis, and advance management of
PCD; in particular to facilitate two-way communication
between basic science and the PCD clinical community,
helping these two communities to come together in
highlighting important gaps in basic knowledge, unmet
clinical needs and ultimately to move novel discoveries
from the bench to the clinic. Major areas of interest
were highlighted during the conference which stimulated
discussion and brought together perspectives from basic
scientists, clinicians, researchers and most importantly,
patient representatives.
BEAT-PCD’s Inaugural Conference was held in South-
ampton, UK in December 2015. We aimed to identify
the research and clinical needs pertinent to diagnosing
and treating patients with PCD. In particular, we wanted
to bring scientists and clinicians together to discuss col-
laborative approaches to expedite drug development
through to clinical trials. We wanted to identify the gaps
in our knowledge around basic science, epidemiology,
clinical care and clinical trials, and identify the gaps that
might be answered with existing data. We additionally
planned to identify approaches and collaborations for
prospective data collection through new studies. The
conference also aimed to develop detailed plans for fu-
ture studies and projects in small groups, including con-
crete ideas for study design, potential collaborators and
funding.
This manuscript summarises the outcomes of the 3-day
Inaugural Conference, which included lectures, break-out
discussion groups, workshops and a poster session. Aims,
projects and major areas of interest from each workgroup
are addressed in separate sections. Highlights from some
of the lectures are captured throughout the manuscript in
boxes, and a large selection of poster titles and authors are
displayed in a table.
Workgroup 1: Basic science
The basic science workgroup (WG1) aims to develop
both a research network and an infrastructure to enable
the sharing of samples, data and state-of-the-art know-
ledge between scientists studying cilia biology and PCD
pathology.
Fig. 1 Diagram of BEAT-PCD Workgroups (WG), overall aims and training opportunities
Fig. 2 Susana Lopes from the Nova Medical School, Universidade Nova de Lisboa, Portugal presented on in vivo models of PCD
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WG1 include:
a) Characterization of PCD causing mutations;
b) Description of pre-clinical PCD models and how
such models can be utilized in developing therapies;
c) Understanding the airway microbiome in PCD
patients; and
d) Application of imaging technologies to facilitate
PCD research and patient diagnostics.
Model organisms have long been used to study motile
cilia. For example, mutant studies in the biflagellate
green alga Chlamydomonas reinhardtii date back many
decades [22]. Current models of ciliary dyskinesia were
presented at the conference (Fig. 2). In order to utilise
these as pre-clinical models, one of the first goals of
WG1 is to summarize the current knowledge regarding
their application in PCD research in a state-of-the-art
manuscript. This will be followed by the evaluation and
subsequent dissemination of existing and newly devel-
oped protocols and standard operation procedures and
ultimately by establishing an online platform and agree-
ment templates that allow the simplified sharing of cells,
tissue and tools between participating researchers.
Mutations in more than thirty genes are known to
underlie PCD [23], raising the likelihood that persona-
lised therapies will need to be developed. Such treat-
ments, targeting specific genetic and/or cellular defects,
seem likely to include gene therapy. Recent proof-of-
principal studies have demonstrated the rescue of ciliary
beating in air-liquid interface (ALI) cultures from PCD
patients. Cells with mutations on DNAI1 (explaining up
to 14% of PCD cases [23]) have been rescued by a virally
delivered mini-gene [24], and cells with a DNAH11 mu-
tation (responsible for approximately 20% of PCD with
normal ultrastructure [23]) have been corrected using
gene editing by a virally encoded transcription activator
like effector nucleases (TALEN) [25]. Such approaches
have yet to be successfully transferred into animal
models, the next step on the road to human trials. The
mouse is the only genetic model with lungs and while
modelling aspects of PCD [26], current mouse models
do not fully recapitulate human pathogenic mutations.
Another objective of WG1 is therefore to foster discus-
sion about the mutations that should be a priority for
genetic modelling, based on current translational and
clinical needs. Through the WG1 network, a research
consortium will need to be formed to apply for funding
from national and international sources to enable devel-
opment of new animal PCD mutants.
Microbiomes have an important role in human physi-
ology and health [27]. However, there is a lack of pub-
lished evidence regarding the role of pathogens in theseverity and progression of PCD. Only recently have mo-
lecular techniques been utilized to identify specific
clones of Pseudomonas Aeruginosa from chronically col-
onized PCD patients [28]. This meeting brought to-
gether a group of scientists and clinicians with interests
in the pulmonary microbiome and PCD. Following pres-
entation (Fig. 3) and discussion of the implications of
how changes in the microbiome might influence PCD
progression (and to what extent such changes either fol-
low or drive PCD pathogenesis), a framework was de-
scribed for an initial pilot study, examining the
microbiota, virome and fungi composition in a cohort of
PCD patients from across Europe.
An important area of PCD research is defining the
boundaries of what is considered to be PCD. There is a
broad spectrum of cilia-related disorders, comprising a
highly heterogeneous group of phenotypically and genet-
ically different diseases; PCD refers to a specific syn-
drome associated with defects of motile cilia but our
definition of PCD is developing in line with increasing
knowledge. Understanding the genetic basis of disorders
that can be associated with PCD (e.g., heterotaxy) may
provide a deeper understanding of classical presentations
of PCD and might challenge our current definition of
PCD (Fig. 4).
Imaging has become central to modern science and
medicine, playing key roles in both the study of cilia
biology and the diagnosis of PCD. At this meeting the
use of High-Speed Video Microscopy to analyse ciliary
beating for diagnosis was discussed and a need for
standardisation of methods and quantitative beat pattern
analysis was identified since qualitative analysis is inher-
ently subjective, even when performed by expert micros-
copists. The role of computer aided analysis was
discussed; a number of talks and posters presented dur-
ing the meeting providing evidence for these discussions.
The group established a plan to share archived video
data (from patient and control samples) for blind com-
putational analysis; this can subsequently be compared
to the original expert qualitative analysis.
The concept of a database, that could incorporate gen-
omic, phenotypic (ciliary motility and ultrastructural
findings) and clinical data (respiratory and other sys-
tems) along with animal model data was debated. This
could also include links to reference databases such as
PubMed, Scopus and could provide an open “one stop”
source of information for PCD researchers.
Work group 2: Epidemiology
The epidemiology workgroup (WG2) aims to improve
our understanding of the epidemiology of PCD. It will
make use of all existing data from PCD patients to gain
essential knowledge on the clinical presentation and nat-
ural history of the disease and on predictors of disease
Fig. 3 Mary Carroll from University Hospital Southampton, UK presented on the microbiome-pointers from CF
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intervention studies but also for standardising and im-
proving future prospective data collection.
Major areas of interest for collaboration identified by
WG2 include:
a) Systematic reviews summarising the available
evidence; and
b) Development of large standardised collaborative
studies by pooling national and regional datasets
into large standardised collaborative studies. ThisFig. 4 Cecilia Lo from the School of Medicine, University of Pittsburgh, USA
the shared genetic aetiology of PCD and heterotaxyincludes the international (iPCD) cohort, a
retrospective cohort of available datasets, and the
prospective international PCD registry. Particular
emphasis will be given to data derived from
recruitment of adult patients.
Few publications are available on the clinical epidemi-
ology of PCD and most come from case reports or small
clinical case series. Many basic questions are un-
answered (Fig. 5). A recent systematic review found only
52 publications that contained clinical information onpresented on pulmonary morbidity in congenital heart disease and
Fig. 5 Claudia Kuehni from the Institute of Social and Preventive Medicine, University of Bern, Switzerland highlighted open questions, gaps and
controversies in PCD epidemiology
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38 patients per study. Results were rarely age-stratified,
outcomes not standardised, and study populations highly
selected as they came from specialised clinics (e.g., pul-
monary, ENT or fertility). Few studies had longitudinal
data, such as changes of lung function over time
[29, 30], and most had been conducted by paediatricians,
resulting in little data from adult patients. However,
while early reports describing children with PCD sug-
gested a relative benign course, recent data from adult
patients demonstrates severe lung disease with chronic
Pseudomonas infection and respiratory failure in many
patients [31].
Available resources to study the epidemiology of PCD
include the two large collaborative datasets that have
been compiled in the framework of the EU-funded FP7
project BESTCILIA:Fig. 6 Myrofora Goutaki from the Institute of Social and Preventive Medicine,
cohort study (iPCD cohort) & other current and future dataa) A retrospective international cohort study (iPCD
cohort) has been constructed by identifying existing
datasets of PCD patients, standardising and
assembling them a retrospective cohort (Fig. 6).
WG2 aims to maintain, expand and enrich, clean
and analyse the data of the iPCD Cohort. Some
contributing partners are adding new patients to
their datasets; others add repeated measurements
(longitudinal data) to patients that have already been
included. Additional groups have expressed an
interest to contribute. A methodological paper
describing the development, dataset and first results
of the iPCD Cohort has been submitted [32].
b) A prospective international PCD registry, also
funded within BESTCILIA, provides a valuable
tool for prospective data collection and future
research [19].University of Bern, Switzerland presented on the international PCD
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inviting more countries and more centres to contribute
data. Particular emphasis will be on recruiting more
adult physicians and including more data on adult pa-
tients. The registry will establish a steering committee,
which will be responsible for managing the registry in
the future, and a framework of agreements regulating
how these data can be used by the scientific community.
In this inaugural meeting, we discussed a list of scientific
publications based on these datasets, which will describe
clinical presentation and long-term prognosis of PCD,
such as body growth, lung growth, lung function decline
with age, development of bronchiectasis and respiratory
insufficiency, and changes of clinical presentation
throughout lifetime. First analyses of the iPCD dataset
will focus on body growth and lung function. Partici-
pants agreed on the importance to apply for funding
from national and international sources to support the
exploitation of the collected data.
The need for standardised clinical data on symptoms
and signs, captured through structured clinical profor-
mas, was an important topic to arise from the discus-
sions. While standardised data are usually available on
results of diagnostics tests, lung function, microbiology
and imaging, the data on the spectrum, frequency and
severity of symptoms (from the patient history), and
physical signs (from the clinical examination) lack details
and are so poorly standardised within and across clinics,
that is difficult, if not impossible to analyse such data in
collaborative studies. Currently PCD centres collect such
information in an open format, or use forms derived
from other respiratory diseases (e.g., cystic fibrosis). The
few clinical proformas that are PCD-specific forms are
not standardised between centres. An important goal of
WG2 is therefore to develop standardised clinical pro-
formas for PCD outpatient clinics. These should enable
standardised monitoring of clinical symptoms and signs
at diagnosis and during follow-up, for different age-
groups. The development of these proformas is a main
focus for the next 2 years and will happen in collabor-
ation with WG4. As a first step we are collecting all
PCD proformas that are currently in use. These will be
used to draft a standardised form, which will be refined
in a Delphi process among paediatric and adult physi-
cians caring for PCD patients.
Screening tools for referral of patients to diagnostic
testing were discussed at some length. These can help
to decide which patients with chronic cough and
rhinitis should be referred to PCD reference centres
for diagnostic testing. One prediction tool (PICADAR)
has been developed and validated in two PCD centres
from the UK, but needs further validation in other
countries, other health care settings and different age
groups of patients [33].Work group 3: Clinical care
The clinical care workgroup (WG3) aims to identify current
and develop future strategies for diagnosis, management
and delivery of care in PCD across Europe and globally.
The mission is to bring together clinicians from multi-
disciplinary backgrounds to work with patient representa-
tives to improve management strategies.
Major areas of interest for collaboration identified by
WG3 include:
a) Identify treatments that could be considered for
clinical trials;
b) Identify treatments already in use that might be
suitable for efficacy testing in (e.g., use of antibiotics
and sinus washes);
c) Investigate differences in delivery of care across
Europe and identify features associated with good
clinical outcome; identify priority areas for
research through surveys and systematic literature
reviews; and
d) Develop evidence based guidelines.
Pseudomonas aeruginosa (PsA) is an opportunistic
pathogen that frequently causes chronic infections in the
upper and lower airways of both PCD and cystic fibrosis
(CF) patients [28, 34]. PCD patients are usually colo-
nised in childhood, where up to one third exhibited at
least one positive sample during a 6 year follow-up but
only 2–5% became chronically infected [30]. Despite in-
tensive antibiotic therapy, prevention of chronic infec-
tion is rarely achieved. Thus, approximately 30% of
Danish PCD patients are chronically infected in early
adulthood [28]. Chronic infection with PsA has been
shown to be associated with lower lung function [31]
and increasing age [7, 28]. In contrast to CF, it was re-
cently shown that chronic infection was cleared for a
minimum of 1 year in 69% of patients following treat-
ment with a course of inhaled and oral antibiotics with
an additional course of intravenous antibiotics every
3 months [28].
A core goal in PCD management is the prompt treat-
ment of new infections through eradication of PsA.
Eradication protocols were recently recommended by
experts [35], and are based on those used in CF. Experts
also recommend treatment of chronic PsA infection,
often based on use of nebulized antibiotics [35] and
some PCD specialist centres advocate the use of long-
term prophylactic antibiotics. The growing problem of
PsA infection in PCD was presented (Fig. 7) and discus-
sions during the workshop sessions revealed differences
in opinion towards treatment strategies to achieve PsA
eradication.
A literature review on eradication studies of Pseudo-
monas Aeruginosa infection in PCD, cystic fibrosis (CF)
Fig. 7 Kim G. Nielsen from the Danish PCD Centre and Paediatric Pulmonary Service, Copenhagen University Hospital, Denmark presented on
Pseudomonas infection - a growing problem in PCD
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available) will be carried out so that possible recommen-
dations can be derived and form the basis for future
randomized clinical trials among best-ranked methods or
treatments for eradication of PsA infection in PCD. Mean-
while a European survey with the specific aim to aggregate
knowledge on various existing treatment regimens regard-
ing PsA infection in PCD is planned with a view to com-
bine results of the review and the survey for intermediate
guidelines to prevent or treat such infections.
Effective treatments for sinus diseases and hearing
problems need to be identified in order to propose treat-
ment modalities that can be the subject of randomised
controlled trials. A recent publication on the clinical ef-
fects of sinus surgery and intensive follow-up in patients
with PCD revealed bacterial sinusitis in 19/20 patients
demonstrating simultaneous sinus and lung infection
with identical pathogen in 13/20 patients [28], highlight-
ing the need for further and larger studies to address the
possible importance of a more aggressive treatmentFig. 8 Hannah Mitchison from University College London, UK presented onapproach towards the inevitable chronic sinusitis in
PCD patients.
An assessment of the risk of cross infection in PCD
was discussed. Similar to CF, the PCD community of pa-
tients and physicians fears interpersonal transmission of
infections; however a previous study investigating cross
infection in 107 PCD patients from a single centre dur-
ing an 11-year follow-up period showed no patient to
patient transmission [28]. Guidelines and recommenda-
tions on the need for cross infection precautions in out-
patient clinics and in relation to patient’s participation in
future meetings are necessary.
Reasons for variations in disease severity and progres-
sion between patients diagnosed with PCD was an area
of interest for WG participants. It is likely that a com-
bination of different factors are responsible for these var-
iations, several of which are being investigated. There
has been growing interest in genotype-phenotype correla-
tions [35–37], with studies reporting milder or more se-
vere phenotypes depending on the genes affected [37–40].PCD genetics as a diagnostic test
Fig. 9 Laura Behan from University of Southamton, UK and University College Cork, Ireland presented on Health related quality of life measures
fro PCD: QOL-PCD
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presented (Fig. 8).
A survey investigating differences in delivery of care for
PCD across Europe was discussed. Questionnaires and in-
depth interviews with PCD specialists from different coun-
tries will provide in-depth information for the development
of a survey, which will collect data from healthcare profes-
sionals involved in PCD diagnostics and management.Work group 4: Clinical trials
The clinical trials workgroup (WG4) aims to develop
the evidence-base to underpin future clinical trials. It
will identify and evaluate clinically relevant outcome
measures for longitudinal monitoring of PCD patients
in clinical care and future trials.
Major areas of interest for collaboration identified by
WG4 include:Fig. 10 Philipp Latzin from the University of Bern and the University of Basa) Enhancing the evidence base for disease-targeted
treatments;
b) Identifying challenges in designing and conducting
clinical trials in PCD; and
c) Deeper phenotyping of PCD patients for better
stratification in clinical trials.
Clinically validated outcome measures are essential for
the reporting of clinical trials and longitudinal studies
[41]. This is particularly important for international col-
laborations and the expansion of ongoing research net-
works [42, 43]. Establishing clear disease-defining and
monitoring outcomes and algorithms would increase
data validity and shareability, and allow for cross-study
comparisons. The development, validation, and transla-
tion of the first outcome measure in PCD, which as-
sesses health related quality of life questionnaire [20],
was presented (Fig. 9).el, Switzerland presented on multiple-breath washout
Fig. 11 Oliver Bieri from the University of Basel, Switzerland presented on lung MRI: overview and application in PCD
The Author(s) BMC Proceedings 2016, 10(Suppl 9):66 Page 14 of 19Previous studies in PCD have used a wide range of
outcomes as surrogate measures for disease severity.
Forced expiratory volume in 1 s as a percentage of pre-
dicted (%FEV1), for example, is frequently used as an in-
dicator for severity of lung disease despite studies
suggesting it might not be appropriate in longitudinal re-
search and clinical trials as a single outcome measure
for early lung disease in PCD [44, 45]. Discussions
highlighted the necessity of identifying other possible
outcome measures for monitoring lung disease progres-
sion and to serve as endpoints in clinical trials, such as
multiple breath wash-outs (MBW), high-resolution com-
puterised tomography and magnetic resonance imaging.
Future applications of MBW and MRI in PCD and as a
potential outcome measure for future clinical trials were
presented at the conference (Figs. 10 and 11). WG4,
thus, aims to review and summarise the existing evi-
dence on the use of outcome measures in PCD. This will
result in a series of systematic reviews, which will iden-
tify and evaluate disease specific outcome measures toFig. 12 Egbert Biesheuvel from the FP7 ASTERIX project presented on met
research in rare diseasesbe recommended for future use. Additionally, partici-
pants agreed on the importance of conducting a review
on outcome measures used in other diseases that share
some similarity with PCD, such as cystic fibrosis and
chronic rhinosinusitis, to suggest outcomes that might
be of relevance but have not yet been used or investi-
gated in PCD. This will result in a positional paper that
will inform future research studies.
Little is known about the natural variability of lung func-
tion parameters in stable patients over time. Correlation of
%FEV1 with other lung function measurements such as
lung clearance index (LCI) has been investigated, with stud-
ies showing conflicting results [46–49]. Furthermore, there
are very few studies [50] investigating the precision of indi-
vidual measurements and no studies investigating repeat-
ability and response to change of respiratory status.
Interventions such as physiotherapy and use of mucolytics
will likely influence lung function parameters. An ongoing
study by Boon et al. is investigating differences in %FEV1
and LCI before and after 20 min of chest physiotherapyhodological approaches to overcome the difficulties of conducting
Table 1 Title, authors and country of first author of 32 posters from 10 countries, presented at the BEAT-PCD Inaugural Conference
(only listed if authors agreed to have the title published)
Poster title Authors (Country of first author)
Opportunities and challenges In the development and evaluation of a
clinical questionnaire for PCD.
Amirav I, Roberts MR, Mussaffi H, Revital A, National Israeli PCD
Consortium, Omran H (Israel)
PCD in Israel: prevalence, clinical features, current diagnosis and
management practices.
Abitbul R, Amirav I, National Israeli PCD Consortium, Omran H, Mussaffi H
(Israel)
Diagnosing primary ciliary dyskinesia; an international patient
perspective.
Behan L, Galvin AD, Masefield S, Copeland F, Manion M, Rindlisbacher B,
Redfern B, Rubbo B, Lucas JS (UK)
Ex-vivo measurement and mathematical model of a flow induced by cilia
motion: application in primary ciliary dyskinesia.
Bottier M, Pena Fernandez M, Blanchon S, Pelle G, Bequignon F, Isabey D,
Coste A, Escudier E, Grotberg JB, Papon JF, Louis B, Filoche M (France)
Physical parameters of metachronal waves in healthy and diseased
human airway epithelium.
Chioccioli M (UK)
The accuracy of nasal nitric oxide testing in PCD diagnostics is
population specific.
Collins SA, Behan L, Evans HJ, Goggin P, Harris A, Jackson C, Packham S,
Walker WT, Lucas JS (UK)
Clinical index to evaluate the risk of primary ciliary dyskinesia in children. Djakow D, Rozehnalova E, Havlisova M, Svobodova T, Pohunek P
(Czech Republic)
Clinical evaluation of primary ciliary dyskinesia patients. Emiralioglu N, Ozcelik U, Tugcu GD, Yalcin E, Ersoz DD, Kiper N (Turkey)
Comparison of bronchoscopy and sputum findings in patients with
primary ciliary dyskinesia.
Emiralioglu N, Sener B, Tugcu GD, Yalcin E, Ersoz DD, Kiper N, Ozcelik U
(Turkey)
Radiological findings of patients with primary ciliary dyskinesia. Emiralioglu N, Oguz B, Gunes A, Yalcin E, Ersoz DD, Kiper N, Ozcelik U
(Turkey)
Therapeutic potential of dynein assembly defects in PCD. Fassad MR, Shoemark A, Patel M, Hayward J, Boustread C, Jenkins L, Cullup
T, Hogg C, Mitchison HM (UK)
Clinical characteristics and follow up in adult patients with primary ciliary
dyskinesia.
Frija-Masson F, Bassinet L, Honore I, Desmazes-Dufeu N, Housset B, Coste
A, Escudier E, Brugel P-R, Maitre B (France)
Diagnosis of primary ciliary dyskinesia (PCD) by transmission electron
microscopy (TEM); validation of a quantitative method.
Goggin P, Page A, Pickering R, Lucas JS (UK)
Growth in patients with primary ciliary dyskinesia (PCD): a multinational
study.
Goutaki M, Spycher B, Maurer E, Meier B, Amirav I, Behan L, Boon M, Carr S,
Casaulta C, Clement A, Crowley S, Dell S, Ferkol T, Haarman E, Karadag B,
Knowles M, Koerner-Rettberg C, Leigh M, Loebinger M, Mazurek H, Morgan
L, Nielsen K, Philipsen M, Sagel S, Santamaria F, Scwerk N, Yiallouros P,
Werner C, Kuehni C (Switzerland)
Lung function in patients with primary ciliary dyskinesia (PCD): a
multinational study.
Halbeisen F, Goutaki M, Maurer E, Boon M, Casaulta C, Clement A, Crowley
S, Haarman E, Karadag B, Koerner-Rettberg C, Mazurek H, Morgan L, Niel-
sen KG, Santamaria F, Schwerk N, Yiallouros P, Latzin P, Lucas JS, Kuehni C
(Switzerland)
Is the portable NIOX MINO reliable for screening nasal nitric oxide levels
in primary ciliary dyskinesia?
Harris A, Bhullar E, Joslin R, Gove K, Lucas JS (UK)
Ready, Steady, Go (RSG): addressing the needs of adolescents in
transition from child to adult services.
Harris A, Maddison J, McGinnity T, Nagra A, Lucas JS (UK)
Ciliary abnormalities in primary ciliopathies: are these also classed as PCD
patients?
Hirst RA, Rutman A, Williams G, Kulkarni N, O’Callaghan C (UK)
Accuracy of primary ciliary dyskinesia diagnostic tests: experience from a
national diagnostic centre [54]
Jackson CL, Behan L, Goggin PM, Adam E, Coles JL, Evans H, Harris A, Lackie
P, Packham S, Page A, Thompson J, Walker W, Kuehni C, Lucas JS (UK)
Evidence for seasonal variation in ciliation of airway epithelial cells
cultured at air-liquid interface; samples for primary ciliary dyskinesia test-
ing [55].
Jackson CL, Coles JL, Thompson J, Lucas JS (UK)
A novel form of PCD that impacts nodal, but not tracheal cilia. Keynton J, Adams E, Riley K, Powles-Glover N, Shinohara K, Lucas J, Lackie
P, Norris D (UK)
Randomized controlled trial to determine the efficacy and safety of
azithromycin maintenance therapy in primary ciliary dyskinesia.
Kobbernagel HE, Buchvald FF, Casaulta C, Collins S, Haarman EG, Hogg C,
Kuehni C, Lucas JS, Omran H, Werner C, Nielsen KG (Denmark)
Electron tomography detects ultrastructural abnormalities in patients
with primary ciliary dyskinesia due to defects in DNAH11.
Kwan R, Burgoyne T, Dixon M, Patel M, Scully J, Onoufriadis A, Hogg C,
Mitchison HM, Shoemark A (UK)
Single breath washout as alternative to multiple breath washout in
patients with primary ciliary dyskinesia (PCD)?
Nyilas S, Schlegtendal A, Yammine S, Casaulta C, Latzin P, Koerner-Rettberg
C (Switzerland)
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(only listed if authors agreed to have the title published) (Continued)
Physiological phenotyping of paediatric chronic obstructive airway
disease [56].
Nyilas S, Singer F, Kumar N, Yammine S, Meier-Girard D, Koerner-Rettberg
C, Casaulta C, Frey U, Latzin P (Switzerland)
Colonization with Pseudomonas aeruginosa in patients with primary
ciliary dyskinesia – a relevant complication?
Price M, Brinkmann G, Hansen G, Schwerk N (Germany)
Growing up with primary ciliary dyskinesia in Bradford: exploring
patients’ experiences as a physiotherapist.
Schofield LM, Horobin HE (UK)
Accuracy of immunofluorescence in the diagnosis of primary ciliary
dyskinesia.
Shoemark A, Frost E, Dixon M, Olloson S, Kilpin K, Bush A, Hogg C (UK)
Impaired childhood growth velocity in patients with primary ciliary
dyskinesia.
Svobodova T, Djakow J, Zemkova D, Cipra A, Pohunek P, Lebl J
(Czech Republic)
Living with primary ciliary dyskinesia. Taelman A, Boon M, Dupont L, Havermans T (Belgium)
The unicellular organism Paramecium as a model system to study PCD. Tassin AM (France)
Paramecium tetraurelia basal body unit isolation for cryo-electron tomog-
raphy studies.
Trepout S, Lemullois M, Guichard P, Koll F,Fleury AA, Beisoon J, Cohen J,
Marco S, Tassin AM (France)
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cussed a framework for an international longitudinal co-
hort study using prospectively collected routine clinical
data to assess the natural variability of lung function pa-
rameters in stable PCD patients. The primary objective is
to identify minimal variations on lung function parame-
ters, upon intervention, that are clinically relevant and
therefore should be taken into consideration when plan-
ning clinical trials and collecting data for longitudinal
studies. One of the main challenges participants identified
was the need to define stability and pulmonary exacerba-
tion. Discussions between WG4 participants revealed that
the definition of exacerbation varied considerably among
PCD specialists; there is a need for a standardised clinical
proforma with a clear definition of pulmonary exacerba-
tion, which was discussed in further details and will be de-
veloped in close collaboration with WG2.
Limitations associated with conducting clinical trials in
rare diseases are well known (e.g., limited study population,
poor phenotyping) [51, 52]. Underpowered studies are par-
ticularly common in PCD; new statistical strategies to deal
with methodological challenges derived from small samples
are being addressed [53]. During the inaugural conference,
participants heard from one of three European consortiumsFig. 13 Amelia Shoemark, PCD diagnostic scientist at The Royal Bromptonworking on developing new statistical methods for rare dis-
eases and small populations (Fig. 12). Collaboration with
these statistical networks will provide an additional toolbox
from which BEAT-PCD members can draw expertise for
new study designs tailored for rare diseases, including the
use of Bayesian and adaptive designs. It was also discussed
that routinely collected data represent a rich and ample
source for research but concerns over data standardisation
across different countries should be fully addressed. An im-
portant step in this direction was the recent establishment
of the European PCD registry [19].
Vision for training school and short term scientific
missions
BEAT-PCD provides an innovative training program for
Early Stage Researchers (ESR) which, with the Action’s
network of experts, consensus guidelines, standardised
protocols and infrastructure, will underpin a global
translational research program of PCD led by European
researchers. A poster session at the BEAT-PCD Inaug-
ural Conference demonstrated the considerable depth
and breadth of research being undertaken by the ESRs
within the COST action. Topics ranged from the devel-
opment of a mathematical model for measurement ofHospital in London, spent 5 days at Rikshospitalet in Oslo, Norway
Fig. 14 Panayiotis Kouis, PhD candidate at the Cyprus University of Technology in Cyprus, spent 3 weeks at the Institute for Social and Preventive
Medicine (ISPM), University of Bern in Switzerland
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to determine the efficacy and safety of azithromycin
maintenance therapy in PCD (Table 1).
Training of ESRs will be conducted through Training
Schools (TS) and Short-Term Scientific Missions
(STSMs) and will ensure sustainability and development
in the field of PCD research. Having trained together
from an early stage, it is anticipated that the scientists
and clinicians will be positioned to continue moving
translational research in PCD forward.
The aim of Training Schools is to widen, broaden and
share knowledge relevant to BEAT-PCD’s objectives
through the delivery of intensive training on new and
emerging subjects. The Training School will establish
themes in its inaugural year that can be developed over
the following three TS. Apart from the lectures delivered
by senior experts in the field, the workshops, poster ses-
sions and short presentations have been designed follow-
ing surveys to the ESRs to fulfil current training needs.
We will gather feedback on the TS and develop ongoing
programmes to extend and develop the programme to
fit emerging science and clinical advances. TrainingFig. 15 Fiona Copeland, chair of the PCD Family Support Group, presentedSchools will provide ESRs with an opportunity to inter-
act and collaborate with senior academics, clinicians,
students, postdoctoral fellows and invited speakers from
both academia and industry at Conferences, Workshops
and Training Schools, thus providing a unique career
development opportunity.
The aim of Short-Term Scientific Missions is to sup-
port individual mobility, strengthen existing networks,
and foster collaborations by allowing ESRs to visit an in-
stitution or laboratory in another participating COST
Country, an approved NNC institution, or an approved
IPC institution. STSMs provide the opportunity for ESRs
to learn from experts in the field by providing the neces-
sary resources for BEAT-PCD members to train with
other PCD teams and/or invite experts in particular
areas and techniques to visit their institution. This ex-
change of experiences promotes standardisation of pro-
cedures across institutions, allows applicants to learn
new techniques or gain access to specific instruments
and/or methods not available in their own institutions,
and provides a platform for career progression for ESRs
as well as development of new ideas between establishedon the patients’ perspective on PCD research
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by competitive applications each year as contributions to
the missions.
Examples of opportunities for STSMs are outlined on
the BEAT-PCD website (http://www.beatpcd.org/). These
include training in PCD diagnostic techniques, systematic
reviews and meta-analysis focused on rare diseases, data
management and statistical methods for multicentre data
analysis, and clinical management for children with PCD
(Figs. 13 and 14). Alternatively individuals can identify
their own needs and liaise directly with specialist centres
to establish a project.
Summary
The BEAT-PCD Inaugural Conference successfully brought
together clinical PCD specialists (paediatricians and adult
pulmonologists, ENT, physiotherapists, specialist nurses)
and scientists from varied backgrounds (genetics, imaging,
cell biology, microbiology, bioinformatics). The multidiscip-
linary conference provided an interactive platform for re-
search groups from twenty countries to exchange ideas
through a program of lectures, poster presentations, break-
out sessions and workshops.
A series of lectures and posters provided an overview
of recent work in the PCD field. Participants heard com-
prehensive talks on the state-of-the-art diagnosis and
management from basic science and clinical perspec-
tives, and on lessons learned from previous research.
The patients’ perspectives on PCD research was deliv-
ered by the Chair of the UK PCD Family Support Group
who highlighted the need for more evidence based treat-
ments, medication with minimal side effects, home
monitoring and better understanding of phenotypes for
which to tailor treatment (Fig. 15). The workshops and
breakout sessions encouraged discussion on gaps in the
current knowledge and the need for research focused on
patient benefit. The conference provided the ideal envir-
onment, bringing together both existing and new poten-
tial collaborators from a wide range of disciplines and
countries. Ongoing projects were discussed and in paral-
lel, new projects developed. The new studies emerged
from both the shared interests of those present as well
as from specific needs identified during the meeting.
Additionally, collaborations between ESRs and senior
experts in different research groups and across special-
ties were encouraged throughout the conference. ESRs
actively participated by chairing and giving lectures, pre-
senting posters, organising breakout sessions and con-
tributing ideas for future projects.
As outlined, a range of highly collaborative projects
were developed as a direct result of this network of ex-
perts coming together. COST-Action provides the perfect
platform to develop and move these projects forward by
enabling networking events such as this one. Theproposed projects are essential for scientific advancement
and translational research and will lead to the improve-
ment of outcomes for patients with PCD. Although pro-
posed projects are ambitious in size and number, the
partnerships formed between research groups will minim-
ise duplication of effort and lost opportunities, therefore
increasing the quantity and quality of scientific output.
The BEAT-PCD network provides a direct pathway facili-
tating the wider dissemination of findings across Europe
and beyond.
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